Organization · Venture Capital
ARTIS Ventures
ARTIS Ventures is a San Francisco-based venture capital firm specializing in early-stage investments at the intersection of technology and biology, known for coining the term 'TechBio'.
Overview
What ARTIS Ventures does
What ARTIS Ventures is
ARTIS Ventures is a San Francisco-based venture capital firm specializing in early-stage investments at the intersection of technology and biology, known for coining the term 'TechBio'.
How it participates in the startup ecosystem
The current public profile supports funder and publisher capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2001
- Approximate age
- About 25 years
- Structured capabilities
- Funder · Publisher
- Last reviewed
- April 23, 2026
Official channels
Find ARTIS Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
ARTIS Ventures as a funder
Investment thesis
ARTIS Ventures focuses on supporting visionary founders who are innovating at the intersection of technology and biology, particularly in critical technologies that enhance human health and resilience.
Focus narrative
ARTIS Ventures invests in startups that leverage technology to transform human health. Their investment strategy is centered around critical innovations in artificial intelligence and engineered technologies, aiming to accelerate the deployment of solutions that enhance health outcomes and societal resilience.
Value beyond capital
ARTIS Ventures provides significant value to its portfolio companies through its in-house scientific expertise, leveraging the TechBio Fellows Program to embed MDs and PhDs within the investment team. This structure supports rigorous due diligence and ongoing assistance to portfolio companies, enhancing their growth and innovation potential.
Terms and economics
- Typical check
- $2,000,000–$15,000,000
Focus and fit
- Stages
- Seed · Series A · Series B
- Regions
- North America · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 7
- Recorded notable exits
- Stemcentrx, Palantir, YouTube, Lemonaid Health, and ViaCyte
Portfolio context
Notable portfolio companies include: YouTube: A platform for video sharing, acquired by Google. Palantir: A data analytics company that went public. Stemcentrx: Focused on precision cancer therapies, acquired by AbbVie. Rad AI: Enhancing radiology efficiency through AI. Conceivable: Working on next-generation fertility science. Freenome: Developing blood tests for early cancer detection.
Capability profile
ARTIS Ventures as a publisher
Editorial focus
ARTIS Ventures is a venture capital firm dedicated to investing in startups that enhance global resilience and protect vital systems for human life. The firm emphasizes health systems, infrastructure, and security frameworks that are scalable and accessible, with a focus on the convergence of technology and biology.
Audience value
ARTIS Ventures provides strategic support to founders at the intersection of technology and biology, aiming to catalyze breakthroughs that improve human health and resilience. The firm offers lifecycle support from initial investment to public offering.
Format and cadence
- Content formats
- blog
- Primary platform
- av.co
- Cadence
- monthly
Availability
- Guest pitch state
- Not currently accepting
Audience and focus
- Audience
- Founders · Investors
- Regions
- North America
Flagship work and coverage
Flagship properties
ARTIS Ventures has a notable portfolio that includes companies such as Eko, which develops non-invasive devices for cardiovascular care; Conceivable, focusing on next-generation fertility science; Rad AI, enhancing efficiency in radiology; Freenome, offering blood tests for early cancer detection; and Modern Meadow, which develops sustainable biomaterials.
Notable coverage
ARTIS Ventures has been featured in various publications for its innovative approach to venture capital, particularly in the TechBio sector, and has a strong historical exit record with notable outcomes including Stemcentrx and Palantir.
Common questions
What to know about ARTIS Ventures
Upseed classifies ARTIS Ventures under the Venture Capital organization type. Its current public profile includes funder and publisher capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 23, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.